Please assess the completion status of the following clinical trial:

Trial Title: Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed acute symptomatic DVT of the lower limbs~Exclusion Criteria:~* Severe concomitant diseases (e.g. renal failure, hepatic failure, uncontrolled hypertension)~* Active bleeding or high risk for bleeding.~* Pregnancy or childbearing potential without proper contraceptive measures.~* Breastfeeding~* Known allergy to idraparinux, SSR126517E, or egg proteins~* Indication of prolonged anticoagulation for other reason than DVT of the lower limbs~* Symptomatic pulmonary embolism (PE)~* Life expectancy \< 6 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Idrabiotaparinux (Type: EXPERIMENTAL): Idrabiotaparinux sodium , 3.0 mg, once-weekly for 6 months.~In avidin sub-study, participants receive on Day 183, avidin 100 mg or placebo (for avidin) (4 hours after Idrabiotaparinux administration)
- Idraparinux (Type: ACTIVE_COMPARATOR): Idraparinux sodium, 2.5 mg, once-weekly for 6 months~In avidin sub-study, participants receive on Day 183, placebo (for avidin) (4 hours after Idrabiotaparinux administration)

Based on this trial design, predict the completion outcome and termination type (if applicable).